XAGE · XBRL financial data

Longevity Health Holdings financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (XAGE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	3,729	(3,729)*	0	12	21	17*	510	504	426	473*	392	396
Cost of goods and services sold	1,544	(1,544)*	0	0	5	1*	241	201	171	205*	155	160
Gross profit	2,185	(2,185)*	0	12	16	16*	270	303	254	268*	237	236
Research and development	1,672	(739)*	429	104	332	189*	197	229	228	104*	55	73
General and administrative	—	—	—	—	—	—	—	1,565	—	—	—	682
Total operating expenses	7,322	(4,141)*	1,380	1,204	1,435	1,023*	1,777	2,161	1,725	2,539*	1,566	960
Operating income (loss)	(5,137)	1,956*	(1,380)	(1,191)	(1,420)	(1,007)*	(1,507)	(1,859)	(1,471)	(2,271)*	(1,328)	(724)
Interest expense	18	15*	12	3	7	7*	5	3	5	6*	3	—
Other income (expense)	13	—	—	20	13	—	—	4	—	—	—	0
Income tax expense (benefit)	0	0*	0	0	0	(97)*	0	0	0	36*	0	0
Net income (loss)	(11,465)	3,157*	(3,271)	(3,305)	(2,878)	(914)*	(1,506)	(1,886)	(1,430)	(2,083)*	(1,432)	(1,883)
Earnings per share, basic USD per share	(0.62)	—	(0.14)	(0.16)	(0.14)	(0.04)*	(1.52)	(1.56)	(0.83)	—	(0.75)	(0.76)
Earnings per share, diluted USD per share	(0.62)	—	(0.14)	(0.16)	(0.14)	(0.04)*	(1.52)	(1.56)	(0.83)	—	(0.75)	—
Weighted average shares, basic thousands of shares	18,630	—	22,915	20,735	20,905	20,905*	991	1,210	1,723	1,782*	1,900	2,475
Weighted average shares, diluted thousands of shares	18,630	—	22,915	20,735	20,905	20,905*	991	1,210	1,723	1,782*	1,900	—

† Share count changed about 1/30 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (XAGE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	7,968	2,912	892	2,198	1,137	157	770	1,551	1,109	707	313	35
Accounts receivable	—	0	—	—	—	4	95	54	47	37	49	20
Inventory	9,808	0	—	114	98	109	1,380	1,173	1,013	963	735	607
Total current assets	38,869	62,900	5,189	4,101	1,885	956	2,793	3,241	2,844	1,950	1,263	712
Property and equipment, net	290	193	170	148	131	114	139	118	117	102	88	76
Right-of-use asset	865	832	798	763	405	385	387	343	322	300	278	255
Goodwill	19,314	—	—	—	—	—	—	—	—	—	—	—
Total assets	82,224	63,949	6,180	5,034	2,442	1,474	3,337	3,719	3,299	2,367	1,642	1,055
Accounts payable	17,790	4,417	4,283	4,095	4,214	4,058	4,599	4,591	4,171	4,495	5,046	5,040
Total current liabilities	37,710	38,502	6,906	5,778	6,174	5,877	6,599	6,914	6,841	7,916	8,349	9,593
Lease liability, non-current	741	698	666	628	333	310	289	263	239	215	188	162
Total liabilities	61,306	39,200	7,572	6,406	6,506	6,187	7,143	7,457	7,276	8,234	8,537	9,755
Accumulated deficit	(61,661)	(58,503)	(61,774)	(65,079)	(67,957)	(68,872)	(70,378)	(72,264)	(73,694)	(75,777)	(77,209)	(79,092)
Total stockholders' equity	20,918	24,749	(1,392)	(1,372)	(4,065)	(4,713)	(3,805)	(3,738)	(3,977)	(5,867)	(6,895)	(8,699)
Total liabilities and equity	82,224	63,949	6,180	5,034	2,442	1,474	3,337	3,719	3,299	2,367	1,642	1,055
Common shares outstanding (cover page) thousands of shares	23,082	19,245	20,803	20,905	20,905	30,120	1,004	1,782	1,782	2,475	2,475	2,475

† Share count changed about 1/30 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (XAGE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(11,465)	3,157*	(3,271)	(3,305)	(2,878)	(914)*	(1,506)	(1,886)	(1,430)	(2,083)*	(1,432)	(1,883)
Stock-based compensation	238*	62*	211	164*	186*	266*	115	194*	190*	194*	146	79*
Depreciation and amortization	429	(383)*	24	24	18	18*	24	22	16	16*	15	13*
Net cash from operating activities	(5,026)*	(3,144)*	(1,076)	(1,138)*	(1,403)*	(772)*	(753)	(836)*	(1,434)*	(306)*	(485)	(224)*
Purchases of property and equipment	0*	0*	—	—	—	—	—	—	—	0*	—	—
Net cash from investing activities	663*	(663)*	(749)	0*	0*	0*	(150)	(15)*	1*	(0)*	—	—
Proceeds from issuing common stock	—	—	—	—	0*	0*	1,638	1,760*	86*	0*	190	0*
Share repurchases	—	0*	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	11,537*	(1,249)*	(196)	2,445*	342*	(208)*	1,516	1,632*	991*	(96)*	92	(54)*

† Share count changed about 1/30 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2840 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2840 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Longevity Health Holdings	35	396	(224)*	2.5M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Caring Brands	1,820	not reported	(463)*	10.4M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
DSwiss	258	512	50*	206.9M	—	Q2 FY26 10-QJun 30, 2026
Scientist Home Future Health	14	212	(45)*	23.7M	—	Q3 FY26 10-QSep 30, 2026
cbdMD	2,118	5,554	(442)*	11.2M	4.8 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.